Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious? by Facciabene, Andrea et al.
© 2012 Landes Bioscience.
Do not distribute.
Know thy enemy
Why are tumor-infiltrating regulatory T cells so deleterious?
Andrea Facciabene, Stephen Santoro and George Coukos*
Ovarian Cancer Research Center; Perelman School of Medicine; University of Pennsylvania; Philadelphia, USA
Keywords: chemokine, CCL28, regulatory T cells, hypoxia, angiogenesis
We recently described hypoxia as one of the leading mechanism for the recruitment of regulatory T cells (Treg) through
CCL28 chemokine in ovarian cancer. Treg promote progression of cancer through tumor-specific immune paralysis but
also reprogramming of angiogenesis. We review these mechanisms and discuss the challenges and opportunities for
therapy targeting Treg.
It has long been recognized that the tumor
microenvironment plays a major role in all
phases of tumor genesis and progression.
The role of the immune system in the
tumor biology is becoming even more
apparent. Its ability to either permit or
restrain the tumor growth relies largely on
a delicate balance between pro-inflamma-
tory and suppressive networks. In ovarian
cancer, and several other tumor types, the
balance between effector and suppressor/
regulatory cells may decide the fate of the
tumor as well as the clinical outcome of
patients.
1-3 T regulatory (Treg) cells are
considered pivotal regulators of immune
suppression and peripheral tolerance; they
are highly enriched in the tumor micro-
environment and are well known for their
role in tumor progression. Indeed, a low
abundance of intratumoral Tregs can
translate into years of added survival,
highlighting the importance of these cells
for tumor progression.
3 Mouse models
further support the role for Tregs in tumor
progression, where depletion of Tregs
facilitates tumor rejection and induction
of antitumor immunity.
4 In addition
Tregs have been also demonstrated to play
a key role in chronic inflammatory
diseases.
5 The mechanisms leading to
Treg accumulation in tumors are not well
understood, although recruitment by
specific chemokines has been long postu-
lated.
3 We recently further characterized
the pathways that drive Tregs into ovarian
cancer and demonstrated a key role for
CCL28 in Treg recruitment, a chemokine
that we found to be directly upregulated
by hypoxia.
6
Tumor progression is critically linked
not only to immune escape but also to the
development of neovasculature or angio-
genesis, required to supply oxygen and
nutrients to rapidly growing tumors.
7 In
the absence of adequate vasculature, tumor
cells undergo hypoxia and starvation,
followed by apoptosis and necrosis, with
release of stress signals including danger
associated molecular pattern (DAMP)
molecules, which could mobilize anti-
tumor immunity. However, in the hypoxic
tumor microenvironment these events fail
to break tolerance to tumor associated
antigens. This observation led us to
postulate that the hypoxic tumor regions
are actively releasing soluble factors that
could recruit immunosuppressive elements
to the tumor microenvironment, thereby
maintaining local tolerance. Through low-
density quantitative polymerase chain
reaction (qPCR) microarray analysis of
primary ovarian cancer cells and cancer cell
lines, we discovered that CCL28 is highly
upregulated under hypoxia, an effect
directly mediated by the hypoxia inducible
factor-1a (HIF-1a). Furthermore, we
observed that overexpression of CCL28
co-localizes with upregulation of HIF-1a
in human ovarian cancers, and it predicts
shortened patient survival.
Recognizing that Treg cells may express
CCR3 and/or CCR10, the two known
receptors for CCL28, we postulated
that secretion of CCL28 chemokine by
hypoxic tumor cells might be acting to
recruit Treg cells to the neoplasm. Using
chemotaxis chambers and neutralizing
antibodies against CCL28 and its two
receptors, we identified the CCL28-
CCR10 interaction as the primary
mediator of Treg cell recruitment to
tumor. To confirm the importance of
CCL28 mediated Treg cell recruitment to
ovarian tumors in vivo, we used the
syngeneic ID8 ovarian cancer model. In
this system, we showed that orthotopic
(intraperitoneal) ID8 tumors, engineered
to overexpress CCL28, accumulated more
CD4
+CD25
+FOXP3
+ Treg cells within
the tumor and showed more aggressive
phenotype than their parent ID8 counter-
parts. Underscoring the critical role these
Treg cells play in tumor progression, mice
depleted of CCR10
+ Treg cells showed
delayed tumor growth. Interestingly, we
also noted that CCL28-overexpressing
intraperitoneal tumors exhibited a higher
density of blood vessels in tumors and
resulted in increased levels of VEGF-A in
the tumor ascites than the parent ID8
tumors. In mice inoculated with CCL28-
overexpressing intraperitoneal tumors,
depletion of CCR10
+ Treg cells restored
VEGF-A levels to those observed in
mice bearing parent ID8 tumors. Taken
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together, these data demonstrate that
recruitment of Treg cells to the tumor
supports disease progression through a
dual mechanism: (1) the canonical sub-
version of antitumor immunity and
(2) through the establishment of a pro-
angiogenic reprogramming of the tumor
microenvironment. As such, depletion of
Treg cells, and/or prevention of their
recruitment to tumors, emerge as critical
elements of antitumor therapy.
The novel findings of our work include
that (1) hypoxia triggers Treg recruit-
ment and (2) Tregs promote angiogenesis.
Tumor hypoxia is known to trigger signals
that promote angiogenesis, remodel the
vasculature and stroma, and promote
metastasis.
8 In this particular instance, we
found that tumor hypoxia triggers recruit-
ment of immunosuppressive Treg cells
through CCL28 upregulation. In turn, the
recruited Treg cells dampen the antitumor
immune response and directly increase
angiogenesis, the latter being teleologi-
cally justified given their recruitment
by hypoxia. These findings support the
notion that tumor immune suppression
and angiogenesis are parallel mechanisms
operating in synchrony and synergy to
render the local microenvironment con-
ducive to tumor growth. Treg can now be
added to a long list of immunosuppressive
tumor-associated host cell populations
which also support angiogenesis pathways,
including M2 macrophages, plasmacytoid
dendritic cells, myeloid derived suppressor
cells, neutrophils, mesenchymal stem
cells and cancer associated fibroblasts.
Furthermore, additional hypoxia mecha-
nisms synergize to enhance the effect of
Tregs, including direct effects on the
Treg cells
9 as well as through paracrine
mediators such as adenosine.
10
The universality of the described
mechanisms for all tumor types has yet
to be established. CCL28 was the main
chemokine upregulated by hypoxic
ovarian cancer cells in vitro and was found
to play an important role in vivo. How-
ever, other tumor types, especially those
arising in extraperitoneal compartments
may use alternate mechanisms. It is con-
ceivable that each tumor type expresses a
unique fingerprint of chemotactic and
paracrine factors, which ultimately deter-
mine the fate and natural history of the
cancer. A complete list of factors that
could make up that fingerprint, and what
their individual significance may be, need
more in-depth investigation. The pro-
posed scenario, however, raises some very
interesting questions: Can progression be
inferred through such signature? Do the
chemokine fingerprints of treatable tumors
differ from those resistant to therapy? Can
we impact these fingerprints and change
them to reverse “do not reject” to “reject”
signals? Finally, although Treg cells appear
to be central in ovarian cancer progression
could there other suppressive populations
be more important in other tumor types?
By moving forward with the goal of under-
standing the crosstalk between the tumor
and the immune system, advancements in
cancer therapy will be sure to follow.
Figure1. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells: (A) Hypoxia upregulates CCL28 expression and recruit Treg
(B) Once in the tumor Treg shut down the antitumor immune response and foster angiogenesis.
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